Soligenix Announces Formation of Behçet's Disease Medical Advisory Board

About this update from Soligenix, Inc.

[{"type":"text","content":"Phase 2a clinical study of SGX945 in Behçet's Disease initiating in 2024\nPRINCETON, N.J., Feb. 8, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the formation of a Medical Advisory Board (MAB) to provide medical/clinical strategic guidance to the Company as it advances the clinical development of SGX945 (dusquetide) for the treatment of Behçet's Disease. The Company previously announced that the U.S. Food and Drug Administration (FDA) had granted Fast Track designation for dusquetide in the treatment of oral lesions of Behçet's Disease.\n\n \n \n \n \n \n \n\n \n\"I am honored to have such a prestigious and dedicated group of physicians committed to working with us as we develop dusquetide therapy for Behçet's Disease,\" stated Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix. \"We have assembled some of the world's leading experts in this field who collectively have hundreds of publications and have the experience of treating thousands of patients with this chronic condition. The initiation of a Phase 2a clinical study in Behçet's Disease later this year will be another important milestone for our company and we look forward to working with the MAB to advance this program.\"\nComprised of internationally renowned rheumatologists with extensive experience in Behçet's Disease, the MAB will play an important advisory role in the conduct of the upcoming Phase 2a clinical study, as well as in the design of subsequent clinical studies and associated regulatory interactions with health authorities. The MAB will provide feedback, input and guidance on clinical strategies and their implementation, as well as on other critical items, such as health economics and reimbursement, to assist Soligenix in meeting the needs of patients suffering from Behçet's Disease.\nThe MAB Members\nGülen Hatemi, MD\nDr. Hatemi is one of the world's leading physicians in the treatment of Behçet's Disease and leads the largest Behçet's research center in the world at Istanbul University – Cerrahpaşa, Behçet's Disease Research Center. Dr. Hatemi has over 250 publications in her field and has conducted numerous clinical research tria...

More updates from Soligenix, Inc.